EFFECTS OF DENOSUMAB ON PAIN AND ANALGESIC USE IN GIANT CELL TUMOUR OF BONE: RESULTS FROM A PHASE 2 STUDY

被引：0

作者：

Broto, J. ^{[1
]}

Cleeland, C. ^{[2
]}

Skubitz, K. ^{[3
]}

Staddon, A. ^{[4
]}

Blum, R. ^{[5
]}

Dominkus, M. ^{[6
]}

Engellau, J. ^{[7
]}

Ganjoo, K. ^{[8
]}

Atchison, C. ^{[9
]}

Qian, Y. ^{[9
]}

Jacobs, I. ^{[9
]}

机构：

[1] Hosp Univ Son Espases, Palma De Mallorca, Spain

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[4] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[5] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA

[6] Med Univ Wien, Vienna, Austria

[7] Skane Univ Hosp, Lund, Sweden

[8] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA

[9] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 9卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：52 / 52

页数：1

共 50 条

[21] Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results From a Phase II Study
Engellau, J.
Chawla, S.
Grimer, R.
Powell, A.
Schuetze, S.
Skubitz, K.
Staddon, A.
Atchison, C.
Zhao, Y.
Jacobs, I.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : 15 - 16
[22] Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.
Blay, J.
Chawla, S. P.
Martin Broto, J.
Choy, E.
Dominkus, M.
Engellau, J.
Grimer, R.
Henshaw, R. M.
Palmerini, E.
Reichardt, P.
Rutkowski, P.
Skubitz, K. M.
Thomas, D. M.
Zhao, Y.
Qian, Y.
Jacobs, I. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Denosumab does not decrease the risk of lung metastases from bone giant cell tumour
Shinji Tsukamoto
Andreas F. Mavrogenis
Giulio Leone
Alberto Righi
Manabu Akahane
Piergiuseppe Tanzi
Akira Kido
Kanya Honoki
Yasuhito Tanaka
Davide Maria Donati
Costantino Errani
International Orthopaedics, 2019, 43 : 483 - 489
[24] The role of Denosumab in joint preservation for patients with giant cell tumour of bone
Perrin, D. L.
Visgauss, J. D.
Wilson, D. A.
Griffin, A. M.
Razak, A. R. Abdul
Ferguson, P. C.
Wunder, J. S.
BONE & JOINT JOURNAL, 2021, 103B (01): : 184 - 191
[25] Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone
Traub, Frank
Singh, Janith
Dickson, Brendan C.
Leung, Stephanie
Mohankumar, Rakesh
Blackstein, Martin E.
Razak, Albiruni R.
Griffin, Anthony M.
Ferguson, Peter C.
Wunder, Jay S.
EUROPEAN JOURNAL OF CANCER, 2016, 59 : 1 - 12
[26] Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study
Thomas, D. M.
Chawla, S.
Skubitz, K.
Staddon, A.
Henshaw, R.
Blay, J.
Smith, J.
Ye, Z.
Roudier, M.
Jun, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[27] Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study
Palmerini, E.
Blay, J-Y.
Le Cesne, A.
Reichardt, P.
Rutkowski, P.
Gelderblom, H.
Grimer, R. J.
Feng, A.
Jandial, D.
Chawla, S.
ANNALS OF ONCOLOGY, 2017, 28
[28] ASSESSMENT OF SURGICAL DOWNSTAGING IN AN OPEN-LABEL PHASE 2 TRIAL OF DENOSUMAB IN PATIENTS WITH GIANT CELL TUMOUR OF BONE
Stalley, Paul D.
Ferrari, Stefano
Rutkowski, Piotr
Grimer, Robert J.
Dijkstra, Sander P. D.
Pienkowski, Andrzej
Vaz, Gualter
Seeger, Leanne L.
Feng, Amy
Bach, Bruce A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 188 - 188
[29] Correction to: Denosumab does not decrease the risk of lung metastases from bone giant cell tumour
Shinji Tsukamoto
Andreas F. Mavrogenis
Giulio Leone
Alberto Righi
Manabu Akahane
Piergiuseppe Tanzi
Akira Kido
Kanya Honoki
Yasuhito Tanaka
Davide Maria Donati
Costantino Errani
International Orthopaedics, 2019, 43 : 491 - 491
[30] Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Palmerini, Emanuela
Seeger, Leanne L.
Gambarotti, Marco
Righi, Alberto
Reichardt, Peter
Bukata, Susan
Blay, Jean-Yves
Dai, Tian
Jandial, Danielle
Picci, Piero
BMC CANCER, 2021, 21 (01)

← 1 2 3 4 5 →